MediWound Ltd. (NASDAQ:MDWD) Receives $33.50 Consensus PT from Analysts

Shares of MediWound Ltd. (NASDAQ:MDWD) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $33.50.

MDWD has been the topic of a number of recent analyst reports. Wall Street Zen raised MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. HC Wainwright reissued a “buy” rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd.

Hedge Funds Weigh In On MediWound

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDWD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares in the last quarter. Rhumbline Advisers grew its stake in MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 481 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares during the period. Marshall Wace LLP acquired a new position in shares of MediWound in the 2nd quarter valued at approximately $317,000. Finally, Menora Mivtachim Holdings LTD. bought a new stake in shares of MediWound during the 2nd quarter worth approximately $339,000. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Stock Up 0.8%

Shares of MDWD stock opened at $17.27 on Thursday. The company has a market capitalization of $221.75 million, a P/E ratio of -9.09 and a beta of 0.13. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50. The firm has a 50-day moving average price of $18.11 and a 200 day moving average price of $17.97.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.57. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. The firm had revenue of $5.43 million for the quarter, compared to analyst estimates of $6.56 million. As a group, research analysts expect that MediWound will post -2.66 earnings per share for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.